Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + ribavirin in genotype 2 chronic hepatitis C
CTR20170117Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sofosbuvir, ribavirin in chronic hepatitis C (CHC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2017; status: completed.
02
Drugs
sofosbuvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on CTR20170117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170117.